We scan new podcasts and send you the top 5 insights daily.
Cyclodextrin dimers sit between 2,000 and 3,000 Daltons, functioning like therapeutic antibodies by sequestering targets without metabolic transformation. Despite exceeding classical size boundaries, they are synthesized via stepwise chemistry and handled by FDA CDER under small molecule regulatory expectations.
Cyclodextrin therapeutics fail to absorb into systemic circulation through the gastrointestinal tract regardless of modifications made to their structure. Consequently, developers must design programs from the outset around subcutaneous injections, self-administered pens, or osmotic pumps rather than attempting oral delivery formulations.
In selecting targets for its macrocyclic peptide platform, Merck strategically prioritizes two factors: 1) extracellular targets that don't require difficult cell penetration, and 2) disease areas where existing options are only injectable. This creates a clear path to differentiation and addresses high unmet patient needs.
Unlike traditional small molecules that need a pocket on a target protein, molecular glues work by changing the surface of an E3 ligase. This modified surface then perfectly matches and binds the target protein, enabling its degradation without requiring a direct drug-to-target binding site.
Partially substituted cyclodextrins generate semi-random, stochastic isomeric mixtures across 21 hydroxyl reaction sites. Instead of purifying a single isomer, developers establish lot-to-lot comparability for regulators by tracking identical 2D NMR and mass spectrometry distribution patterns alongside in vitro safety and activity assays.
Modeling and synthesizing beta cyclodextrins into head-to-head dimers enabled the encapsulation of oxidized cholesterol targets. Rather than simply doubling binding affinity by linking two monomers, this specific asymmetric configuration achieved roughly a thousandfold affinity increase over monomeric cyclodextrin.
Although cyclodextrin building blocks are biological products generated by microbial enzymes, decades of commercial use in foods and solvents matured their extraction. This industrial scale allows modern therapeutics to source ultrapure starting materials cheaply at scale without investing in complex upstream fermentation development.
Mini-proteins are framed as a superior drug modality that merges the key strengths of traditional therapies. They possess the high selectivity characteristic of biologics like antibodies, while also having the stability and formulation advantages of small-molecule drugs. This combination allows them to precisely target difficult receptors while avoiding common off-target effects or instability issues.
Macrocyclic peptides are large enough to disrupt difficult protein-protein interactions (like biologics) but small enough to be orally bioavailable (like small molecules). This new modality can tackle targets previously undruggable by conventional small molecules, creating a best-of-both-worlds therapeutic.
Regulatory bodies like the FDA demand comprehensive characterization for any novel excipient, not just the API. For new delivery vehicles, every new lipid or protein component must be fully understood and proven safe, receiving the same level of scrutiny as the drug substance itself.
Antibodies bind to specific amino acid sequences, making them unable to distinguish between a protein's healthy and toxic structural forms. Alt-Pep's synthetic peptides use a complementary structure (alpha-sheet) to selectively bind only the toxic oligomers, enabling both targeted therapy and highly specific diagnostics.